News & Updates

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024 byStephen Padilla

In patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy (LOT), treatment with belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPD) results in statistically significant and clinically meaningful progressive-free survival (PFS) compared with pomalidomide plus bortezomib and dexamethasone (PVD), as shown in the DREAMM-8 study.

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024
Fenofibrate staves off vision loss in diabetes
Fenofibrate staves off vision loss in diabetes
08 Aug 2024 byElvira Manzano

The antilipidemic drug fenofibrate averts or delays diabetic retinopathy (DR) in diabetes patients with early retinal changes in the LENS trial, potentially paving the way for the least invasive route of drug delivery in this population.

Fenofibrate staves off vision loss in diabetes
08 Aug 2024